Loading data for CLDI — first visit, this takes a few seconds.
Calidi Biotherapeutics, Inc. (CLDI)
NYSE American: CLDI
· 实时价格 · USD
1.33
+0.02 (1.53%)
收盘价： Sep 02, 2026, 8:00 PM
1.40
+4.48%
盘后: 7:30 PM
股价、关键数字和最新消息，都在这一页。
Calidi Biotherapeutics, Inc.（CLDI）股价、分析与数据
暂无数据
| 买价 | 1.32 |
| 市值 | 3.46M |
| 营收（TTM） | n/a |
| 净利润（TTM） | -23.5M |
| 1.33 | |
| -37.04 | |
| n/a | |
| -1.49 | |
| 市净率（TTM） | 0.89 |
| 市销率（TTM） | 0.00 |
| 财报日期 | n/a |
| 卖价 | 1.34 |
| 成交量 | 5,248 |
| 20日均量 | 306,023 |
| 开盘价 | 1.33 |
| 前收盘价 | 1.31 |
| 日内区间 | 1.33 - 1.33 |
| 52周区间 | 1.25 - 27.84 |
| 分析师 | n/a |
| 目标价 | n/a |
| 分红 | n/a |
| 除息日 | n/a |
关于 CLDI
Calidi Biotherapeutics, Inc., a biotechnology company, develops targeted therapies to deliver genetic medicines to distal sites of disease. The company offers CLD-101, which is in Phase 1b/2 clinical trial for the treatment of newly diagnosed high grade glioma, as well as in Phase 1 dose-escalation clinical trial for recurrent high-grade glioma; CLD-201 product for solid tumors, such as breast cancer, head and neck cancer, and sarcoma; and CLD-40...
公司完整简介财报意外
Calidi Biotherapeutics 已于 Nov 13, 2025 发布季度财报：
- 营收为 $0 低于预期 $0, ， NaN% 同比增长.
- 每股收益为 -35.36 低于预期 -8.48, ， 71.67% 同比增长.